[go: up one dir, main page]

UA106907C2 - Stabilized pharmaceutical composition - Google Patents

Stabilized pharmaceutical composition

Info

Publication number
UA106907C2
UA106907C2 UAA201211360A UAA201211360A UA106907C2 UA 106907 C2 UA106907 C2 UA 106907C2 UA A201211360 A UAA201211360 A UA A201211360A UA A201211360 A UAA201211360 A UA A201211360A UA 106907 C2 UA106907 C2 UA 106907C2
Authority
UA
Ukraine
Prior art keywords
pharmaceutical composition
stabilized pharmaceutical
disease
stabilized
pregabalin
Prior art date
Application number
UAA201211360A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Камала С. Ядав
Аміта П. Сурана
Санджавані А. Кукарні
Рашмі Р. Прасейд
Original Assignee
Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг filed Critical Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг
Publication of UA106907C2 publication Critical patent/UA106907C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to stabilized pharmaceutical composition comprising pregabalin and a disaccharide obtained from isomalt, lactitol, maltitol as stabilizer and optionally a conventional pharmaceutically acceptable carrier. The stabilized pharmaceutical composition according to the invention is useful in the treatment of a number of diseases such as epilepsy, Alzheimer's disease or Parkinson's disease.
UAA201211360A 2010-03-01 2011-03-01 Stabilized pharmaceutical composition UA106907C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU1000120A HU230031B1 (en) 2010-03-01 2010-03-01 Stabilized pharmaceutical composition containing pregabalin and isomalt
PCT/HU2011/000019 WO2011107812A2 (en) 2010-03-01 2011-03-01 Stabilized pharmaceutical composition

Publications (1)

Publication Number Publication Date
UA106907C2 true UA106907C2 (en) 2014-10-27

Family

ID=89989589

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201211360A UA106907C2 (en) 2010-03-01 2011-03-01 Stabilized pharmaceutical composition

Country Status (10)

Country Link
US (1) US8968780B2 (en)
EP (1) EP2542229A2 (en)
CN (1) CN102869350A (en)
BR (1) BR112012022255A2 (en)
EA (1) EA021719B1 (en)
HU (1) HU230031B1 (en)
MA (1) MA34090B1 (en)
UA (1) UA106907C2 (en)
WO (1) WO2011107812A2 (en)
ZA (1) ZA201207375B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain
CN103494796B (en) * 2013-09-30 2016-01-20 浙江华义医药有限公司 Pharmaceutical composition that lyrica is stable and preparation method thereof
CN104694355B (en) * 2015-03-20 2016-09-28 吉林大学 Radix Puerariae liver-protection health-care wine and preparation method thereof
JP6919119B2 (en) * 2017-01-23 2021-08-18 日新製薬株式会社 A compressed solid pharmaceutical composition containing a γ-aminobutyric acid derivative substituted at the 3-position.
WO2019009927A1 (en) * 2017-07-06 2019-01-10 Adorus Pharmaceuticals Llc Blend compositions for oral administration as a rapidly dissolving powder and/or suspension
JP6504638B1 (en) * 2018-05-31 2019-04-24 武田テバファーマ株式会社 Tablet and method for producing the same
CN110613689A (en) * 2018-06-19 2019-12-27 北京万全德众医药生物技术有限公司 Orally disintegrating tablet containing amphiphilic polymer-pregabalin compound
WO2024165618A1 (en) 2023-02-07 2024-08-15 Kinast Lasse An immediate-release tablet of pregabalin with an increased percentage api content

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928183A1 (en) 1989-08-25 1991-02-28 Goedecke Ag LACTAM-FREE CYCLIC AMINO ACIDS
US6197819B1 (en) 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
DE9321600U1 (en) 1993-05-06 2000-04-06 Südzucker Aktiengesellschaft Mannheim/Ochsenfurt, 68165 Mannheim Sweeteners
CN1094757C (en) 1996-07-24 2002-11-27 沃尼尔·朗伯公司 Isobutylgaba and its derivatives for the treatment of pain
HRP980342A2 (en) 1997-06-25 1999-02-28 Warner Lambert Co Anti-inflammatory method
US6127418A (en) 1997-08-20 2000-10-03 Warner-Lambert Company GABA analogs to prevent and treat gastrointestinal damage
EP1077692B1 (en) 1998-05-15 2004-07-28 Warner-Lambert Company LLC Amino acid stabilized gabapentin and pregabalin preparations and process for preparing the same
HU228772B1 (en) 1998-05-15 2013-05-28 Warner Lambert Co Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
FR2781793B1 (en) 1998-08-03 2001-07-20 Prographarm Lab PROCESS FOR PRODUCING COATED GABAPENTINE GRANULES
US7022678B2 (en) * 2001-03-30 2006-04-04 Warner-Lambert Company Pregabalin lactose conjugates
JP2004534764A (en) 2001-05-25 2004-11-18 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Liquid pharmaceutical composition
WO2003080588A1 (en) 2002-03-20 2003-10-02 Xenoport Cyclic 1-(acyloxy)-alkyl prodrugs of gaba analogs, compositions and uses thereof
WO2005051384A1 (en) 2003-11-25 2005-06-09 Pfizer Limited Stabilised pharmaceutical compositions
EP1543831A1 (en) 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
ITMI20041447A1 (en) 2004-07-20 2004-10-20 Zambon Spa PHARMACEUTICAL COMPOSITION INCLUDING GABAPENTINA
NL2000281C2 (en) * 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
WO2007107835A2 (en) * 2006-03-17 2007-09-27 Aurobindo Pharma Limited Stable liquid formulations of antiepileptic agents
CN1827590A (en) * 2006-04-14 2006-09-06 北京润德康医药技术有限公司 Novel pregabalin crystalline form, its preparing process and pharmaceutical compositions thereof
DE102006030642A1 (en) 2006-07-03 2008-01-10 Conti Temic Microelectronic Gmbh identification system
JP2011504491A (en) * 2007-11-23 2011-02-10 ルピン・リミテッド Controlled release pharmaceutical composition of pregabalin

Also Published As

Publication number Publication date
EP2542229A2 (en) 2013-01-09
HUP1000120A2 (en) 2011-09-28
US20130064893A1 (en) 2013-03-14
WO2011107812A3 (en) 2011-11-10
EA021719B1 (en) 2015-08-31
ZA201207375B (en) 2014-03-26
BR112012022255A2 (en) 2016-10-25
CN102869350A (en) 2013-01-09
WO2011107812A2 (en) 2011-09-09
MA34090B1 (en) 2013-03-05
EA201290856A1 (en) 2013-02-28
HU1000120D0 (en) 2010-04-28
HU230031B1 (en) 2015-05-28
US8968780B2 (en) 2015-03-03

Similar Documents

Publication Publication Date Title
UA106907C2 (en) Stabilized pharmaceutical composition
MX2012009079A (en) Extended release formulations of rasagiline and uses thereof.
ZA201100034B (en) Pharmaceutical compositions for treatment of parkinson's disease
MY156302A (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF ß-AMYLOID DISEASES AND SYNUCLEINOPATHIES
EA201171088A1 (en) TREATMENT OF DISKINESIA IN DIFFERENT DISORDERS
EA200970287A1 (en) METHODS, COMPOUNDS, COMPOSITIONS AND MEDIA SUITABLE FOR DELIVERY OF 3-AMINO-1-PROPANSULPHONE ACID
WO2012075492A3 (en) Carbocycle-substituted purine and 7-deazapurine compounds
GT201300165A (en) COMPOUNDS AND ITS USE AS BACE INHIBITORS
NZ631601A (en) Solid forms of a thiophosphoramidate nucleotide prodrug
MX2010013766A (en) Rasagiline for parkinson's disease modification.
WO2008154083A3 (en) Compounds, compositions and methods for the treatment of synucleinopathies
NZ599880A (en) Use of bethanechol for treatment of xerostomia
MX2012007273A (en) Pteridinones as inhibitors of polo - like kinase.
MY156288A (en) Pharmaceutical formulations containing dopamine receptor ligands.
MY156434A (en) Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
MY179527A (en) Catecholamine derivatives useful for the treatment of parkinson's disease
WO2012021629A3 (en) Novel d3 dopamine receptor agonists to treat dyskinesia in parkinson's disease
MX2009004908A (en) Chemical compounds.
WO2011023367A3 (en) Bisphosphonate-prodrugs
EA201171087A1 (en) METHODS OF ADMINISTRATION (4aR, 10aR) -1-n-PROPIL-1,2,3,4,4a, 5,10,10a-OCTAGHYDROBENZO [g] KHINOLIN-6,7-DIOLA AND RELATED COMPOUNDS THROUGH THE IMMABLE SHELL OF THE CAVITY SLIM OF THE NOSE OR SKIN AND PHARMACEUTICAL COMPOSITIONS ON THEIR BASIS
WO2012048129A3 (en) Inhibitors of polo-like kinase
MX2015001917A (en) Pharmaceutical compositions of memantine.
WO2010127143A3 (en) Neuroprotective ganoderma compositions and methods of use
MY189740A (en) Butylphthalide-telmisartan heterocomplex, preparation method and application thereof
MX350195B (en) Cystamine analogues for the treatment of parkinson's disease.